RxDoctor Payments Data

Craig Rackley, MD

Pulmonary Disease · Durham, NCNPI 1750548400

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $22,891 of the $32,543 with a category attached, or 70.3%. 12 manufacturers reported payments, led by Genentech USA, Inc. at 35.6% of the total. Reporting peaked in 2019 at $22,886 and has fallen 94.0% since, to $1,371 in 2024. Among pulmonary disease clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$32,543in general payments, 2019–2025

Across 47 payments — averaging $692.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$12K
  • Boehringer Ingelheim$11K
  • Roche Diagnostics International Ltd$8K
  • BD$2K
  • Livanova USA, Inc.$176
  • Abiomed$169
  • plus $376 from 6 others
$90,583in research payments, 2019–2025

Across 19 payments — averaging $4767.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Mallinckrodt Hospital Products Inc.$46K
  • Mallinckrodt Enterprises LLC$45K

What the payments were for

  • Consulting fees$4,41014%
  • Speaking & faculty fees$22,89170%
  • Travel & lodging$3,74212%
  • Food & beverage$1,4534%
  • Education$460%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,543 in reported general payments places this provider in the 90th percentile of 393 pulmonary disease providers in North Carolina.

See all pulmonary disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$41,086
Medicare patients
79
Services billed
301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →